Introduction
============

Lung cancer is the most common cancer worldwide and also represented the most common death in Taiwan. Based on the National Health Insurance Research Database published in Taiwan, the 5-year survival rate of lung cancer patients was 15.9% [@B1]. The 2015 WHO classification relies on a greater extent of immunohistochemical characterizeation, which allows for precise subtyping, conduction of appropriate treatment strategy, and predicting clinical course. Moreover, the molecular characterization of patients with non-small cell lung cell (NSCLC) is resulting in the use of agents with high levels of antitumor activity, particularly for those with driver mutations [@B2]. The most notorious ones are the mutations in the epidermal growth factor receptor (*EGFR*) and rearrangement of the anaplastic lymphoma kinase (*ALK*) gene or *ROS1* gene, and mutation in *BRAF* V600E. Mutations in the *EGFR* tyrosine kinase are noticed in lung adenocarcinoma and occur more frequently in females and non-smokers [@B3]. In Asia, the incidence of *EGFR* mutation goes even up to 62% [@B4].

E-cadherin (*CDH1* gene) is a Ca^2+^ dependent homotypic cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells altogether and functions as a binding partner for β-catenin [@B5]. The E-cadherin plays a key role in cellular adhesion, and its down-regulation is potentially important and highly associated with greater tumor metastasis [@B6]-[@B10]. E-cadherin is regarded as an important factor for Epithelial- mesenchymal transition (EMT), which is the critical step for cancer metastasis [@B11], [@B12].

Of recent knowledge, EMT is associated with the mutant status of *EGFR* and the efficacy of EGFR-tyrosine kinase inhibitors (TKIs) in lung cancer cell lines as well as NSCLC patients. Also, the reduction of E-cadherin expression predicts worse overall survival (OS) and disease-free survival/ progression-free survival (DFS/PFS) in patients with NSCLC [@B13], [@B14]. Furthermore, decreased expression of E-cadherin was associated with decreased sensitivity to EGFR-TKIs, whereas high E-cadherin expression improved tumor cells\' sensitivity to EGFR-TKIs [@B15]. However, the correlation between *CDH1* gene polymorphisms and *EGFR* mutations of lung adenocarcinoma has not been well-studied. In this study, we hypothesized that the genetic polymorphisms of *CDH1* (rs16260 and rs9929218) may have an effect on the TK-domain mutations of *EGFR* in patients with lung adenocarcinoma.

Material and Methods
====================

Study Population
----------------

Between years 2012 and 2015, a total of 280 patients with lung adenocarcinoma at Cheng-Ching General Hospital in Taichung, Taiwan were recruited. The study was approved by the Institutional Review Board of Cheng-Ching General Hospital (No. HP120009; 22 September 2012). All enrolled patients provided signed informed consent to participate in this study.

Study Variables
---------------

The main endpoint of the present study was the prevalence of *EGFR* mutation among these lung adenocarcinoma patients, and its association with E-cadherin (*CDH1*) genotypes. We selected two *CDH1* SNPs, including rs16260 (-160, C/A) in the promoter region and the intron 2 variant rs9929218 based on their potential involvement in the various cancer types [@B16]-[@B20]. Different associating factors relating to the mutations in *EGFR* were considered and analyzed as previously described [@B21], [@B22]. Data obtained from medical record of each patient included demographics (age, gender), tobacco smoking status, and tumor staging and differentiation.

Patients Specimens for Genomic DNA Extraction and E-cadherin (*CDH1*) Genotyping
--------------------------------------------------------------------------------

Venipuncture was performed and withdrawn blood from each participant into Vacutainer blood collection tubes containing EDTA and stored at 4℃. Genomic DNA was extracted from QIAamp DNA blood mini kits according to the manufacturer\'s instructions as previously described [@B23]. Allelic discrimination of *CDH1* rs16260 (C_11934298_10) and rs9929218 (C_11509221_10) gene polymorphisms was assessed with the ABI StepOne™ Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and analyzed using SDS version 3.0 software (Applied Biosystems) with the TaqMan assay.

Statistical Analysis
--------------------

Categorical variables, including demographics, smoking status, tumor characteristics, and genotypes polymorphisms, were summarized as number and percentage by *EGFR* mutation status; continuous variables were expressed as mean and standard deviation. The distributions of demographics, clinical characteristics and genotype frequencies among lung adenocarcinoma patients, as well as clinicopathological features in different genotypes, were analyzed with a χ2-test. A p-value of \<0.05 indicated statistically significant.

Results
=======

Characteristics of Study Population
-----------------------------------

This study included a total of 280 patients, 127 males and 153 females with a mean age of 65 years, for analysis. The baseline demographics and clinical characteristic of enrolled patients were shown in Table [1](#T1){ref-type="table"}. There were 111 (39.6%) and 169 (60.4%) patients in the *EGFR* wild-type and mutation type groups, respectively. These two groups differed with respect to gender, tobacco smoking status, and tumor differentiation (p**\<**0.001). The *EGFR* mutation type group, compared with subjects in the *EGFR* wild-type group, were predominantly female (64.5% vs. 39.6%, respectively), non-smoker status (77.5% vs. 45.0%), and mostly well-differentiated (12.4% vs. 7.2%) and moderately-differentiated tumor (81.7% vs. 72.1%).

Distribution of *CDH1* Genotypes of Study Population and Its Association with EGFR Mutation by Gender Difference
----------------------------------------------------------------------------------------------------------------

The distribution frequency of *CDH1* genotypes (rs16260 and rs9929218) of patients with lung adenocarcinoma was shown in Table [2](#T2){ref-type="table"}. The alleles with the highest distribution frequency for rs16260 and rs9929218 in the enrolled patients were homozygous C/C and homozygous G/G for both *EGFR* wild-type and mutation type groups, respectively. After adjusting for variance, there was no significant difference between the wild-type and mutation type of *EGFR* and polymorphisms of the *CDH1* genotypes in rs16260 and rs9929218, when compared with wild-type individuals.

To elucidate the association between the polymorphism of *CDH1* gene and *EGFR* mutations in different gender, the distribution frequency of *CDH1* single nucleotide polymorphism (SNP) (rs16260 and rs9929218) of *EGFR* wild-type and mutation type in lung adenocarcinoma patients was estimated in Table [2](#T2){ref-type="table"}. In females, CA and CA + AA genotypes of *CDH1* rs16260 were significantly reverse associated with *EGFR* mutation type (AOR = 0.43, 95% CI = 0.20-0.92 and AOR = 0.46, 95% CI = 0.22-0.96, respectively). Hence, further analyses were focused on the association between the polymorphism of *CDH1* gene and *EGFR* hotspot mutations in female patients with lung adenocarcinoma.

Association between Polymorphisms of *CDH1* genotypes and EGFR Hotspot Mutations among the Female Lung Adenocarcinoma Patients
------------------------------------------------------------------------------------------------------------------------------

Table [3](#T3){ref-type="table"} showed the association between the polymorphisms of *CDH1* and the *EGFR* hotspot mutation in the female patients. Also, the significantly reverse associations between CA and CA + AA genotypes of *CDH1* rs16260 and EGFR hotspot mutations, namely L858R mutation (OR = 0.40, 95% CI = 0.18-0.90 and OR = 0.44, 95% CI = 0.20-0.97, respectively) and exon 19 in-frame deletion (OR = 0.39, 95% CI = 0.16-0.95 and OR = 0.41, 95% CI = 0.17-0.97, respectively), were demonstrated.

Association between *CDH1* SNP rs16260 and Tumor Classification among Male Lung Adenocarcinoma Patients
-------------------------------------------------------------------------------------------------------

The AJCC Tumor, Node, Metastasis (TNM) staging system for lung cancer (NSCLC) is an internationally accepted system to describe the extent of disease [@B24]. It combines features of the tumor into disease stage groups that correlate with survival and are linked to recommendations for treatment, as well as an indicator of prognosis. In this study, we further investigated the association between polymorphisms of *CDH1* gene and clinicopathologic characteristics among male patients with lung adenocarcinoma. As shown in Table [4](#T4){ref-type="table"}, CA + AA genotype of *CDH1* rs16260 was noted significantly reverse associated with the "T" classification (primary tumor size and extension) based on eighth edition of AJCC TNM staging system (OR = 0.31, 95% CI = 0.12-0.80; p = 0.012). Furthermore, while stratified male patients based on *EGFR* mutation status, consistent reverse association was seen in the mutation type male patients (OR = 0.20, 95% CI = 0.04-0.99; p = 0.037). These findings indicated that the polymorphisms of *CDH1* rs16260 may be associated with the tumor size and extension of lung cancer.

Discussion
==========

Our study investigated 280 patients with lung adenocarcinoma, and the role of E-cadherin (*CDH1*) gene polymorphism in regards to the *EGFR* mutation status, as well as a possible prognostic marker for tumor invasiveness and metastasis and predictive marker for the resistance of EGFR-TKI therapy. The significance of E-cadherin (*CDH1*) polymorphism, as an important epithelial marker/factor of EMT, have been well-studied and established in several human cancers, such as breast cancer [@B25], [@B26], gastric cancer [@B27], pancreatic cancer, ovarian cancer [@B28], [@B29], prostate cancer [@B26], esophageal squamous cell carcinoma [@B30], head and neck cancer [@B31] and skin cancer [@B32]-[@B34]. Regard to lung cancers, though E-cadherin is highly associated with risk of NSCLC carcinogenesis [@B14], [@B35], [@B36], particular adenocarcinoma, the mutant status of *EGFR*, the efficacy of EGFR-TKIs therapy [@B37], and survival prognosis, no study exploring the relationship between *CDH1* gene polymorphisms and the mutations of *EGFR* of lung cancers was conducted. To our best knowledge, this is the first time discovering the statistically significant association between *CDH1* SNP rs16260 variant types (CA and CA + AA genotypes) and hotspot mutations (in-frame deletion mutation in exon 19 and L858R mutation) of *EGFR*, especially in the female lung adenocarcinoma patients.

Advanced NSCLCs that contains characteristic mutations in *EGFR* are highly sensitive to EGFR-TKIs. The previous study has reported that *EGFR* mutation was more prevalent in adenocarcinoma than other types of NSCLCs, as well as female and non-smokers [@B3]. The Asian population has the highest incidence of *EGFR* mutation in the world [@B4]. In Taiwan, Hsu et al. performed a study based on the National Taiwan Lung Cancer Registry and detected the *EGFR* mutation rate higher than 50% [@B38]. Indeed, as shown in our results, higher frequency of *EGFR* mutation type was observed in the female patients (female vs. male = 64.5% vs. 35.5%) and in non-smokers (non-smoker vs. smoker = 77.5% vs. 22.5%). These results were consistent with previous studies indicating that the mutation of *EGFR* was associated with gender, adenocarcinoma, and smoking status [@B3], [@B4], [@B38].

There were very limited studies investigating polymorphisms of different EMT-related genes expression and their relationship with carcinogenesis. Xie et al. [@B39] have reported lately that EMT-related gene variants, namely *ADGRF1*, *NOTCH3,* and *CDH1*, may be involved in susceptibility to NSCLC. Cai et al. [@B40] earlier revealed that genetic effect of a nonsynonymous *HRH4* polymorphism (rs11662595) is a loss-of-function polymorphism that results in dysfunction of *HRH4* gene and attenuates the anti-EMT function of *HRH4* in NSCLC. This investigation provides a promising biomarker for prognosis and therapy of NSCLC. Kim S et al. [@B41] also demonstrates that EMT phenotype was related to PD-L1 overexpression in pulmonary adenocarcinoma cells and patients with EMT-phenotype pulmonary adenocarcinoma may benefit from PD-1/PD-L1-blocking immunotherapy. But to the detail of *CDH1* gene polymorphisms and their association with *EGFR* mutation status, no specific research was found prior to ours.

Our findings relative to association between *CDH1* polymorphism and *EGFR* mutation status suggested CA and CA + AA genotypes of *CDH1* SNP rs16260 were significantly reverse associated with *EGFR* mutation type in female patients with lung adenocarcinoma (AOR = 0.43, 95% CI = 0.20-0.92 and AOR = 0.46, 95% CI = 0.22-0.96, respectively), as compared to the control (CC genotype). AA genotype of the same SNP also showed the same direction of association (AOR = 0.72, 95% CI = 0.13-3.90), but did not reach statistical significance. We further verified this association with the use of two *EGFR* hotspot mutations, namely L858R mutation and in-frame deletion mutation in exon 19, and obtained the consistent statistically significant relationship. These results may explain that *CDH1* variant type is less associated with *EGFR* mutation type especially among the female population; in the other words, *CDH1* wild type (CC genotype) is more related to mutate *EGFR* tyrosine kinase, which is a more favorable prognosis and strongly predicts for sensitivity to EGFR-TKIs. However, the mechanism by which this SNP (rs16260) modulates the roles of female lung adenocarcinoma patients should be further investigated.

Among male lung adenocarcinoma patients, we found no statistical significance between *CDH1* polymorphism and *EGFR* mutation status. But when we further stratified them based on tumor characteristic of AJCC "T" classification (primary tumor size and extension),*CDH1* rs16260 variant type (CA + AA genotype) showed significantly reverse association as T classification progressed, as compared with the control type (CC genotype). This association was still seen in male patients with mutated *EGFR* gene. In the previous studies, downregulation of E-cadherin expression is highly associated with cancer progression and metastasis [@B13], [@B42]-[@B45]. The inclusion of other clinicopathologic parameters at molecular level should be further investigated.

In conclusion, our results suggested that E-cadherin gene (*CDH1*) variants are significantly reverse associated with mutation of *EGFR* tyrosine kinase, especially among the female patients with lung adenocarcinoma. This may be utilized as a prognostic factor for tumor size in Taiwanese patients with lung adenocarcinoma.

###### 

Baseline demographic and clinical characteristics of patients with lung adenocarcinoma by EGFR mutation status (N=280)

  ------------------------------------------------------------------------------
  Variable                           Wild-type\      EGFR mutation\   p-value
                                     (N=111)         (N=169)          
  ---------------------------------- --------------- ---------------- ----------
  **Age, n (%)**                                                      

  \<30                               1 (0.9%)        1 (0.6%)         p=0.657

  30-39                              3 (2.7%)        2 (1.2%)         

  40-49                              11 (9.9%)       16 (9.5%)        

  50-59                              21 (18.9%)      44 (26.0%)       

  60-69                              26 (23.4%)      31 (18.3%)       

  ≥70                                49 (44.1%)      75 (44.4%)       

  Mean ± SD                          65.36 ± 13.42   65.76 ± 13.57    p=0.810

  **Gender, n (%)**                                                   

  Male                               67 (60.4%)      60 (35.5%)       p\<0.001

  Female                             44 (39.6%)      109 (64.5%)      

  **Tobacco smoking, n (%)**                                          

  Non-smoker                         50 (45.0%)      131 (77.5%)      p\<0.001

  Smoker                             61 (55.0%)      38 (22.5%)       

  Pack-years ± SD                    46.32 ± 28.21   19.94 ± 23.83    p\<0.001

  **Tumor AJCC staging, n (%)**                                       

  IA                                 11 (9.9%)       17 (10.1%)       p=0.570

  IB                                 9 (8.1%)        23 (13.6%)       

  IIA                                5 (4.5%)        7 (4.1%)         

  IIB                                1 (0.9%)        0 (0%)           

  IIIA                               10 (9.0%)       11 (6.5%)        

  IIIB                               17 (15.3%)      19 (11.2%)       

  IV                                 58 (52.3%)      92 (54.4%)       

  **Tumor differentiation, n (%)**                                    

  Well                               8 (7.2%)        21 (12.4%)       p=0.001

  Moderate                           80 (72.1%)      138 (81.7%)      

  Poor                               23 (20.7%)      10 (5.9%)        
  ------------------------------------------------------------------------------

###### 

Distribution frequency of *CDH1* genotypes of patients with lung adenocarcinoma and multiple logistic regression analysis of EGFR mutation association

                         All cases (N=280)   Male (N=127)   Female (N=153)                                                                             
  ---------------------- ------------------- -------------- ------------------ ------------ ------------ ------------------- ------------ ------------ -------------------
  ***CDH1* rs16260**                                                                                                                                   
  CC                     55 (49.5%)          90 (53.3%)     1.00               38 (56.7%)   26 (43.3%)   1.00                17 (38.6%)   64 (58.7%)   1.00
  CA                     49 (44.1%)          70 (41.4%)     0.90 (0.53-1.53)   24 (35.8%)   31 (51.7%)   1.95 (0.92-4.14)    25 (56.8%)   39 (35.8%)   0.43 (0.20-0.92)
  AA                     7 (6.3%)            9 (5.3%)       0.81 (0.27-2.45)   5 (7.5%)     3 (5.0%)     0.90 (0.19-4.31)    2 (4.6%)     6 (5.5%)     0.72 (0.13-3.90)
  CA+AA                  56 (50.5%)          79 (46.7%)     0.89 (0.54-1.48)   29 (43.3%)   34 (56.7%)   1.77(0.85-3.65)     27 (61.4%)   45(41.3%)    0.46 (0.22-0.96)
  ***CDH1* rs9929218**                                                                                                                                 
  GG                     68 (61.3%)          108 (63.9%)    1.00               43 (64.2%)   34 (56.7%)   1.00                25 (56.8%)   74 (67.9%)   1.00
  GA                     41 (36.9%)          56 (33.1%)     0.87 (0.51-1.49)   23 (34.3%)   25 (41.7%)   1.37 (0.65-2.89)    18 (40.9%)   31 (28.4%)   0.54 (0.25-1.15)
  AA                     2 (1.8%)            5 (3.0%)       1.17 (0.21-6.57)   1 (1.5%)     1 (1.6%)     0.99 (0.05-18.34)   1 (2.3%)     4 (3.7%)     1.14 (0.12-10.79)
  GA+AA                  43 (38.7%)          61 (36.1%)     0.89 (0.52-1.50)   24 (35.8%)   26 (43.3%)   1.36 (0.65-2.83)    19 (56.8%)   35 (32.1%)   0.57 (0.27-1.20)

The AORs with 95% CIs were estimated by multiple logistic regression models after controlling for age and smoking.

Note: Bold text indicated a significant association with p value \<0.05.

Abbreviations: SNP, single nucleotide polymorphism; AOR, adjusted odds ratio; CI, confidence interval.

###### 

The associations between the polymorphisms of *CDH1* and the EGFR hotspot mutations in female patients with lung adenocarcinoma.

  --------------------------------------------------------------------------------------------------------------------------
                  Wild-type    L858R                            Exon 19 in-frame deletion                
  --------------- ------------ ------------ ------------------- --------------------------- ------------ -------------------
  ***CDH1***\                                                                                            
  **rs16260**                                                                                            

  CC              17 (38.6%)   36 (59.0%)   1.00                                            26 (60.5%)   1.00

  CA              25 (56.8%)   21 (34.4%)   0.40 (0.18-0.90)                                15 (34.9%)   0.39 (0.16-0.95)

  AA              2 (4.6%)     4 (6.6%)     0.94 (0.16-5.67)                                2 (4.6%)     0.65 (0.08-5.10)

  CA+AA           27 (61.4%)   25 (41.0%)   0.44 (0.20-0.97)                                17 (39.5%)   0.41 (0.17-0.97)

  ***CDH1***\                                                                                            
  **rs9929218**                                                                                          

  GG              25 (56.8%)   41 (67.2%)   1.00                                            29 (67.4%)   1.00

  GA              18 (40.9%)   17 (27.9%)   0.58 (0.25-1.32)                                13 (30.2%)   0.62 (0.26-1.52)

  AA              1 (2.3%)     3 (4.9%)     1.83 (0.18-18.56)                               1 (2.3%)     0.86 (0.05-14.51)

  GA+AA           19 (43.2%)   20 (32.8%)   0.64 (0.29-1.43)                                14 (32.6%)   0.64 (0.27-1.52)
  --------------------------------------------------------------------------------------------------------------------------

Note: bold text indicated a significant association with p value \<0.05.

Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

###### 

The associations between polymorphic genotypes of *CDH1* rs16260 and clinicopathologic characteristics of male patients with lung adenocarcinoma.

                                  Tumor AJCC "T" Classification                                        
  ------------------------------- ------------------------------- ------------- ---------------------- -------------
  **All cases (N=127)**           **(N=25)**                      **(N=102)**                          
  ***CDH1* rs16260**                                                                                   
  CC                              7 (28.0%)                       57 (55.9%)    1.00                   
  CA+AA                           18 (72.0%)                      45 (44.1%)    **0.31 (0.12-0.80)**   **p=0.012**
                                                                                                       
  **EGFR Wild type (N=67)**       **(N=13)**                      **(N=54)**                           
  ***CDH1* rs16260**                                                                                   
  CC                              5 (38.5%)                       33 (61.1%)    1.00                   
  CA+AA                           8 (61.5%)                       21 (38.9%)    0.40 (0.12-1.38)       p=0.139
                                                                                                       
  **EGFR Mutation type (N=60)**   **(N=12)**                      **(N=48)**                           
  ***CDH1* rs16260**                                                                                   
  CC                              2 (16.7%)                       24 (50.0%)    1.00                   
  CA+AA                           10 (83.3%)                      24 (50.0%)    **0.20 (0.04-0.99)**   **p=0.037**

Note: bold text indicated a significant association with p value \<0.05.

Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.
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